Vaccinia Viral Vector Service
Creative BioMart Vir-Sci is devoted to improving the safety of vaccinia virus (VV or VACV) vectors and reducing the risk of cytopathic effects in gene therapy research. We have many years of experience in vaccinia virus vector, and can provide fast and satisfactory vaccinia virus vector service according to customer needs. We provide a one-stop service for your project to design and construct appropriate gene delivery vectors.
Vaccinia Virus
Vaccinia virus is a double-stranded DNA virus with a genome of about 190 kb and is a large DNA virus. Vaccinia virus is different from all other viruses in that it has two forms, IMV without envelope and EEV with envelope. Vaccinia virus infections are usually very mild, and although they may cause rashes and fevers, they usually do not cause symptoms in healthy individuals. The immune response from vaccinia virus infection can protect people from deadly smallpox infections. For this reason, vaccinia virus has been used as a live virus vaccine against smallpox in the past. Unlike vaccines that are vaccinated with a weakened form of vaccine, vaccinia virus vaccine does not cause smallpox infection because it does not contain smallpox virus. However, certain complications and adverse vaccine reactions may occasionally occur. People with low immune function can greatly increase this situation. About one in every one million people will have a fatal response to the vaccine.
Figure 1. Vaccinia virus. (Cyrklaff, et al.2005)
Features
- Vaccinia viral vector is a highly immunogenic virus that may be particularly useful in cancer treatment, and can cause strong T cell mediated and antibody responses.
- Vaccinia viral vector has a wide range of hosts.
- Vaccinia viral vector infection and subsequent gene expression are highly efficient.
- The cytoplasmic replication of viruses reduces the chance of viral DNA recombination or integration into normal cells, and its DNA-based genome also makes it more stable than RNA-based viruses.
- Recombinant Vaccinia viral vector with large and several transgenes can be constructed efficiently.
- Vaccinia viral vector can be easily produced to relatively high titers, and the particles are stable and can be stored frozen in solution or in dry powder form for a long period of time without significantly reducing infectivity.
Our service
Creative BioMart Vir-Sci platform provides a comprehensive portfolio of vaccinia viral vector services for the efficient design, development, manufacturing, and analytical testing of viral vector products. So far, we have developed an effective method for generating recombinant oncolytic viruses, including insertion and deletion of GOI in vaccinia viruses. We also provide customized proof-of-concept studies of vaccinia virus.
Application Field
- Transgene delivery.
- VACV equipped with cytokines/ immunostimulatory molecules
- VACV delivers anti-angiogenic agents.
- Optical imaging and deep tissue imaging.
- Preclinical research and drug development.
Workflow of Services at Creative BioMart Vir-Sci
We guarantee strict control of each experimental step in the production process to ensure high quality and high yield of vaccinia virus vectors. Creative BioMart Vir-Sci is committed to providing highly attenuated, host-restricted, non-replicative or poorly replicable vaccinia virus strains to meet the needs of multiple gene delivery in global gene therapy. If you need related services, please feel free to contact us. Our expert team will design high-quality vaccinia virus vectors according to your needs and provide you with professional and thoughtful services.
References
- Altenburg, A.; et al. Modified Vaccinia Virus Ankara (MVA) as Production Platform for Vaccines against Influenza and Other Viral Respiratory Diseases. Viruses, 2014, 6(7), 2735–2761.
- Cyrklaff, M.; et al. Cryo-electron tomography of vaccinia virus. Proceedings of the National Academy of ences of the United States of America, 2005, 102(8): 2772-2777.